


Available online at www.sciencedirect.com

SciVerse ScienceDirect

www.elsevier.com/locate/jprot

Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines☆

Rosa Musso^a, Gianluca Di Cara^a, Nadia Ninfa Albanese^{a,d}, Maria Rita Marabeti^a, Patrizia Cancemi^{a,c}, Dèsirèè Martini^e, Ester Orsini^e, Carla Giordano^{a,b}, Ida Pucci-Minafra^{a,*}

^aCenter of Experimental Oncobiology (C.OB.S.), “La Maddalena” Hospital III Level Oncological Dept., Palermo, Italy

^bBiomedical Department of Internal and Specialist Medicine (Di.Bi.M.I.S.), Endocrinology Section, University of Palermo, Palermo, Italy

^cDepartment of Molecular and Biomolecular Science and Technology (STEMBIO), University of Palermo, Palermo, Italy

^dDepartment of Physics and Chemistry, University of Palermo, Palermo, Italy

^eDepartment of Human Anatomical Sciences and Physiopathology of Locomotor Apparatus, Human Anatomy Section, University of Bologna, Bologna, Italy

ARTICLE INFO

Article history:

Received 17 November 2012

Accepted 22 January 2013

Keywords:

Thyroid cancer

Papillary

Anaplastic

BCPAP cells

8505C cells

Proteomics

ABSTRACT

Thyroid carcinomas account for a minority of all malignant tumours but, after those of the gonads, they represent the most common forms of endocrine cancers. They include several types, among which the *papillary thyroid cancer* (PTC) and the *anaplastic thyroid cancer* (ATC) are the best known. The two histotypes display significant biological and clinical differences: PTC is a well differentiated form of tumour with a high incidence and a good prognosis, while the ATC is less frequent but represents one of the most aggressive endocrine tumours with morphological features of an undifferentiated type. To date, as far as we know, no conclusive studies, useful to design arrays of molecular markers, have been published illustrating the phenotypic and proteomic differences between these two tumours. The aim of this work was to perform a comparative analysis of two thyroid cancer cell lines, derived respectively from papillary (BCPAP) and anaplastic (8505C) thyroid carcinomas. The comparative analysis included cell behaviour assays and proteomic analysis by 2D-PAGE and mass spectrometry. The results have highlighted a new proteomic signature for the anaplastic carcinoma-derived cells, consistent with their high proliferation rate, motility propensity and metabolic shift, in relation to the well-differentiated PTC cells.

This article is part of a Special Issue entitled: From Genome to Proteome: Open Innovations.

© 2013 Published by Elsevier B.V.

1. Introduction

The human thyroid gland is composed of a basic structural unit, the *follicle*, consisting of a monolayer of well polarized cells, the *thyrocytes*, responsible for the T3/T4 hormone secretion, and of other peripheral cells, the *parafollicular C cells*, responsible for the secretion of calcitonin. The presence within the follicle of stem

cells, or remnants of embryonic cells, has been hypothesized as the target cells for tumour initiation. A thin extracellular matrix, which includes occasional fibroblasts and inflammatory cells, is peripheral to the follicle structure.

Thyroid carcinomas account for 1–2% of all malignant tumours and, after those of the gonads, they represent the most common tumours of the endocrine system. The thyroid

☆ This article is part of a Special Issue entitled: From Genome to Proteome: Open Innovations.

* Corresponding author at: Center of Experimental Oncobiology (C.OB.S.), “La Maddalena” Hospital III Level Oncological Dept., Via San Lorenzo Colli 112d, 90146 Palermo, Italy. Tel.: +39 0916806418; fax: +39 0916806418.

E-mail address: ida.pucci@unipa.it (I. Pucci-Minafra).

tumours include several histotypes with different molecular profiles, as well as biological and clinical behaviours.

Among these, papillary (PTC) and anaplastic (ATC) histotypes are probably the most investigated. The two histotypes display significant phenotypic differences, as well as dissimilar clinical occurrences and outcomes. Indeed, PTC is a well differentiated form of tumour with a high incidence, representing approximately 80% of all thyroid tumours and is characterized by a good prognosis [1]. On the contrary, ATC accounts for less than 5%, but it is one of the most aggressive endocrine tumours with morphological features of an undifferentiated type.

However, to date no studies have definitely demonstrated whether malignant forms of thyroid tumours arise from the adult epithelial cells through multistep cancerogenesis [2] or from remnants of foetal thyroid cells [3] or, as more recently hypothesized, from resident stem cells [4–6].

Many genetic alterations have been described as involved in the progression, mostly leading to the anomalous activation of the MAP kinase pathway. Several studies have suggested that BRAF^(V600E) mutation (90% of all BRAF mutations) plays an important role in the early steps of the thyroid carcinogenesis leading to the progression towards the anaplastic forms [7–10], but some controversies about its significance still remain.

Therefore, the biological mechanisms of thyroid cancerogenesis are still unclear. This is also because the panels of putative biomarkers for thyroid cancer histotypes are not yet adequate enough to fulfil the requirements for molecular diagnosis, prognosis and target therapy. We suggest that the increase in knowledge of protein expression in thyroid tumours, as for the breast cancer [11–13], could greatly help to understand molecular mechanisms involved in the thyroid carcinogenesis. With this aim, we performed a comparative analysis of two thyroid cancer cell lines, derived respectively from papillary (BCPAP) and anaplastic (8505C) thyroid carcinomas. The comparative analysis included cell behaviour assays, proteomic analysis by 2D-PAGE and mass spectrometry.

First of all, in this study we show that both PTC and ATC cell lines closely maintain *in vitro* phenotypical characteristics, probably resembling their *in vivo* counterparts. Indeed, the 8505C cells are characterized by cell traits and a behaviour typical of the aggressive phenotype associated with an advanced stage of the disease. On the contrary, the BCPAP cells derived from a more differentiated tumour, maintain *in vitro* a rather stable phenotype and the ability to reorganize “follicle-like” structures. Our findings confirm that these cell lines represent an important model for the *in vitro* study of differentiated and undifferentiated thyroid tumours and may offer new insights into the thyroid carcinogenesis. The proteomic study revealed a panel of differentially expressed proteins, instrumental for cancer growth and invasion, which may be used for future applications as biomarkers of thyroid malignancy.

2. Materials and methods

2.1. Cell culture

The human papillary thyroid carcinoma cell line, BCPAP established in 1992 [14] and human anaplastic thyroid carcinoma cell line, 8505C established in 1994 [15] were

provided by the Endocrinology Laboratory of Prof. C. Giordano. Cells were seeded at a density of 10^4 cells/cm² and grown in RPMI 1640 (GIBCO), supplemented with 10% foetal bovine serum (GIBCO), 1% L-glutamine, 1% penicillin and 1% streptomycin in a humidified incubator with 5% CO₂ in air at 37 °C.

2.1.1. Cell proliferation

The assay [16] was performed by the use of a colorimetric tetrazolium compound (CellTiter 96, Promega). Briefly, 20 µl of CellTiter 96 was added to 100 µl of medium into each well containing the cells. After 1 h of incubation in a humidified 5% CO₂ atmosphere, the absorbance at 492 nm was read using a 96-well plate reader (Amersham).

2.1.2. Scratch assay

The confluent mono-layers of BCPAP and 8505C cells were scraped with a p200 pipet tip. Following the “scratch”, the cells debris were removed by several washes with phosphate-buffered saline (PBS) and fresh growth medium was added. The assays were monitored at different times (6 h–24 h) through optical microscopy.

2.2. Gelatin zymography

2.2.1. Conditioned media preparations

Conditioned media of BCPAP and 8505C confluent cells were collected after 24 h of culture in absence of serum. The media were then submitted to extensive dialysis against ultrapure distilled water at 4 °C and lyophilized. Dried samples were solubilized in a buffer 50 mM Tris-HCl, pH 7.5.

2.2.2. Zymographic assay

Aliquots corresponding to 10 µg were used for mono-dimensional gelatin zymography, that was performed under non-reducing conditions, on 7.5% SDS-PAGE copolymerized with 0.1% gelatin, using a minigel lab apparatus (Biorad). Following the electrophoresis, the SDS was removed from the gel by washes of 1 h with 2.5% Triton-X 100 in 50 mM Tris-HCl, pH 7.5. The zymogram was subsequently developed for 18 h at 37 °C in a buffer containing 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl and 10 mM CaCl₂ [17]. Gel was stained with Coomassie blue and unstained areas corresponding to zones of digestion were visualized after destaining with 7% methanol in 5% acetic acid.

2.2.3. Western blotting

Zymographic controls were performed by western blot assay with purified samples of proMMP-2 and proMMP-9 (kindly donated by Dr H. Nagase, Imperial College, UK), probed respectively with one of the two monoclonal antibody: anti-MMP-2 mouse mAb (1:1000; Santa Cruz, Heidelberg, Germany) and anti-MMP-9 mouse mAb (1:1000; Santa Cruz). Following incubation with the appropriate peroxidase-linked antibody [horseradish peroxidase-conjugated goat anti-mouse IgG (1:3000; Santa Cruz)], the reaction was revealed by the ECL detection system, using high performance films (Hyperfilm ECL; Amersham).

2.3. Scanning electron microscopy (SEM)

BCPAP and 8505C cells were seeded in T-25 cell culture flasks at a concentration of 15×10^3 cell/cm² and were processed for

SEM observation, performed at the Human Anatomy Section, University of Bologna, Italy. The cell culture flasks were carefully rinsed with PBS to prevent the cells detachment. Cells were fixed with Karnowski solution (1.5% glutaraldehyde, 1% paraformaldehyde, 1% cacodylate buffer, pH 7.4) for 10 min. Flasks with adhering cells were then rinsed three times with 0.1% cacodylate buffer, postfixed for 20 min with 1% OsO₄ in cacodylate buffer, dehydrated with ethanol, and finally dried with hexamethyldisilazane (Sigma) for 15 min, as described [18]. Then the specimens were coated with 20 nm-thick palladium-gold film and examined using a Philips SEM 515 at 15 kV.

2.4. Two dimensional gel electrophoresis

2.4.1. Sample preparations

Cells were grown in the presence of serum until 80–90% confluence, then they were serum starved for 24 h, harvested with cell scraper in PBS and lysed in M-RIPA buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA) added with a mixture of protease inhibitors (0.01% aprotinin, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM PMSF). The whole cellular lysate was centrifuged at 14,000 rpm for 8 min to clear cell debris and stored at –80 °C. Protein concentration in the cellular extracts was determined using the Bradford method [19].

2.4.2. 2D-IPG

Cell lysates of BCPAP and 8505C cells were submitted to extensive dialysis against ultrapure distilled water at 4 °C and lyophilized. Dried samples were solubilized in a buffer containing 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 40 mM Tris, 65 mM 1, 4 dithioerythritol (DTE) and a trace of bromophenol blue in 8 M urea. Aliquots of 45 µg (analytical gels) or 1.5 mg (preparative gels) of total proteins were separately mixed with 350 µl of rehydration solution containing 8 M urea, 2% CHAPS, 10 mM DTE and 0.5% carrier ampholytes (Resolyte 3.5–10; Amersham), and applied for isoelectrofocusing (IEF) using commercial sigmoidal IPG strips, 18 cm long with pH range 3.0–10; (Bio-rad, Segrate, Milano, Italy). The IEF was carried out by linearly increasing the voltage from 200 to 3500 V during the first 3 h, after which focusing was continued at 8000 V for 8 h. After the run the IPG strips were equilibrated with a solution containing 6 M urea, 30% glycerol, 2% Sodium Dodecyl Sulphate (SDS), 0.05 M Tris-HCl, pH 6.8 and 2% DTE for 12 min, in order to re-solubilize the proteins and reduce the disulphuric bonds. The –SH groups were then blocked by substituting the DTE with 2.5% iodoacetamide in the equilibrating buffer. The focused proteins were then separated on 9–16% linear gradient polyacrylamide gels (SDS-PAGE) with a constant current of 20 mA/gel at 10 °C and the separated proteins were visualized by ammoniacal silver staining [20].

2.4.3. Image acquisition and data analysis

Silver-stained gels were digitized using a computing densitometer and analyzed with ImageMaster 2D PLATINUM software (Amersham Biosciences, Sweden). Gel calibration was carried out using an internal standard and the support of the ExPaSy molecular biology server, as described elsewhere [21]. Quantitative variations in the protein expression levels were calculated as

the volume of the spots (i.e. integration of optical density over the spot area). In order to correct for differences in gel staining, the spot volumes relative to the sum of the volume of all spots on each gel (%Vol) were calculated by the software.

2.5. Protein identification

2.5.1. N-Terminal microsequencing

It was performed by automated Edman degradation in a protein sequencer (Procise 419; Applied Biosystems), as previously described [22].

2.5.2. In-gel digestion and MALDI-TOF analysis

Mass spectrometric sequencing was performed with the Voyager DE-PRO (Applied Biosystems) mass spectrometer as described elsewhere [12]. Briefly, proteins were digested using sequencing-grade trypsin (20 µg/vial). The tryptic peptide extracts were dried and re-dissolved in 10 µl of 0.1% trifluoroacetic acid (TFA). The matrix, R-cyano-4-hydroxycinnamic acid (HCCA), was purchased from Sigma-Aldrich. A saturated solution of HCCA (1 µl) at 2 mg/200 µl in CH₃CN/H₂O (50:50 v/v) containing 0.1% TFA was mixed with 1 µl of peptide solution on the MALDI plate and left to dry. MALDI-TOF mass spectra were recorded in the 500–5000 Da mass range, using a minimum of 100 shots of laser per spectrum. Delayed extraction source and reflector equipment allowed sufficient resolution to consider MH± of mono-isotopic peptide masses. Internal calibration was carried out using trypsin autolysis fragments at m/z 842.5100, 1045.5642, and 2211.1046 Da. Peptide mass fingerprinting was compared to the theoretical masses from the Swiss-Prot or NCBI sequence databases using Mascot (<http://www.matrixscience.com/>). Typical search parameters were as follows: 50 ppm of mass tolerance, carbamidomethylation of cysteine residues, one missed enzymatic cleavage for trypsin, a minimum of four peptide mass hits was required for a match, methionine residues could be considered in oxidized form.

3. Results

3.1. Cell morphology

Fig. 1 shows the representative optical and scanning electron micrographs of BCPAP and 8505C cells. BCPAP cells (Fig. 1(A)) grow in monolayer and exhibit a roughly uniform size with an apparent smooth regular surface, which at SEM (Fig. 1(C)) appears decorated by short microvillous expansions.

At sub-confluence most of the cells produce circular structures of variable size (Fig. 1(A)), often delimiting small central cavities, probably corresponding to the “holes” described by Fabien et al. [23], which mimic the thyroid follicles. In contrast, the 8505C cells manifest very irregular cellular shapes, sizes and contours. They show a tendency to overgrow in multilayer and to produce long cell surface protrusions of variable size, observable at both optical (Fig. 1(B)) and scanning microscopy (Fig. 1(D)).

3.2. Cell proliferation

Fig. 2 shows the growth curves of BCPAP and 8505C cells where each point represents the mean of three replicates




Fig. 1 – Representative micrographs of BCPAP and 8505C cells. The figure shows the optical micrographs: A) BCPAP; B) 8505C (magnification: 20 \times); and scanning electron micrographs: C) BCPAP; D) 8505C (magnification: 500 \times).

from three independent experiments (\pm SD). Cell proliferation was evaluated every day from the first 24 h until 9 days after seeding. As can be observed, the difference in cell proliferation between the two cell lines is evident at 4 days from seeding, where the cell density of 8505C cell line is \sim 30% higher with respect to B-CPAP cell line. From the 7th day on, this difference is significantly reduced in conjunction with the cellular over-confluence decay of both cell lines.




Fig. 2 – Proliferation assay of thyroid cancer cells at different times. Diagram illustrates the growth rate of BCPAP (continuous line) and 8505C (dotted line) cells, by using the MTS colorimetric assay.

3.3. Proteomic analysis

Representative 2D proteomic maps of BCPAP and 8505C cells are shown in Fig. 3. The protein identities are marked with labels corresponding to the accession numbers of the Swiss-Prot database and the different isoforms of the same protein are jointly labelled.

In the present study we have identified 223 protein forms, corresponding to 147 genes, by MALDI-TOF and/or N terminal sequencing (for more details see the Supplementary Table with the catalogue of identified proteins).

For the comparative analysis of protein expression, the average of three spot values from three different BCPAP and 8505C cells gels was utilized (Fig. 4) and protein levels were considered significantly different for \geq 2-fold variation (Fig. 5). Out of the 223 identified proteins, 63 protein forms, corresponding to 50 genes, were found to be differentially expressed in 8505C in comparison with BCPAP cells.

The catalogue of differentially expressed proteins is reported in Table 1 with the following information: protein name, access number of Swiss-Prot database, protein abbreviated names, theoretical and experimental pI and MW, identification methods, matched masses/searched masses ratio and number of peptide matches that covered the regions of the protein sequence.

These proteins were clustered into 9 functional categories, mainly according to the current ontology database [i.e. 24], with the abrogation of the redundancy. Proteins




Fig. 3 – Representative 2D proteomic maps of BCPAP and 8505C cells. 2-DE separation was performed on IPG gel strips (18 cm, 3.5–10 NL) followed by the SDS-PAGE on a vertical linear-gradient slab gel (9–16%T). Protein spots of known identity are labelled with the access number of the Swiss-Prot/TrEMBL database. When present, different isoforms of the same protein are jointly labelled.

with multifunctional activities were sorted according to their major function.

Fig. 4 shows the graphs illustrating the relative differences in density values (expressed as Vol%) of protein spots from BCPAP (grey colour) and 8505C (black colour) cells. As shown, the two curves display significant divergences, at various degrees of amplitude in a number of proteins. Analytically, the nine protein classes are the following:

3.3.1. Metabolic processes

This class represents the most abundant among those identified in our system. It contains 17 protein forms corresponding to 12 isoforms of glycolytic enzymes, 2 mitochondrial proteins and 3 proteins of other metabolic processes. It is interesting the finding that all the identified glycolytic enzymes, including their isoforms, i.e.: ENOA, G3P, PGK1, KPYM, LDHA and TPIS, display a higher expression level in 8505C cells with respect to the BCPAP. These enzymes are key components of the glycolytic metabolism, but they are also involved in additional functions. Concurrently, the two proteins of the mitochondrial compartment, ECHM and VATF, appeared at lower intensity levels in the 8505C.

3.3.2. Cytoskeleton and associated proteins

This cluster includes 9 protein forms corresponding to 7 genes. Higher expression levels in 8505C regarded: COF1, PROF1, VINC, TBB5 and VIME, the latter almost absent in the BCPAP cells. In contrast, two epithelial markers, i.e. K1C9 and K2C8, and an actin isoform displayed a lower intensity in 8505C than in BCPAP cells.

3.3.3. Membrane-associated proteins with multiple activities

This group includes 4 protein forms. Three of which, LEG1, ANXA1 and ANXA2, showed higher expression levels in 8505C cells while a lower expression level was observed for the ANXA4.

3.3.4. Calcium binding proteins

Proteins within this cluster include 6 protein forms corresponding to 5 genes. Five of these proteins belong to the S100 family and four of them (two isoforms of S100P, S10A7 and S10AD) appeared less expressed in the 8505C cells, as did the calmodulin, a multifunctional calcium transducer; while the S10A6 appeared more expressed in 8505C cells.

3.3.5. Regulators of cell proliferation

This class includes 5 protein forms. All these proteins (MIF, NTF2, CCNH and SPB5), except AGR2, are characterized by higher expression levels in the 8505C cells.

3.3.6. Molecular chaperones/heat shock proteins

This group comprises 9 protein forms corresponding to 5 genes. It is interesting to note that all these proteins, including their isoforms (CH60, CH10, GRP75, HYOU1 and PDIA3) displayed lower expression levels in 8505C.

3.3.7. Detoxification processes

This class consists of 6 protein forms, four of which (AK1BA, 3HDH, PRDX1, and AK1C3) were under-expressed, while two of them were highly expressed (LGUL and SODM) in 8505C cells. An altered expression of proteins of the antioxidant protective system has been also reported by other authors [25] in the poorly differentiated ARO cells (from anaplastic carcinoma) with respect to TPC-1 cells (from papillary carcinoma).

3.3.8. Degradation machinery

This cluster includes 3 protein forms: UCHL1 with a high expression level in 8505C cells, and two subunits of the proteasome (PSA1 and PSB4) showing lower expression levels.




Fig. 4 – Global proteomic profiles of BCPAP and 8505C cells. The diagram shows the relative differences in density values (expressed as Vol%) of protein spots from BCPAP (grey colour) and 8505C (black colour) cells. Each value is the mean of three independent determinations.




Fig. 5 – Histogram of differentially expressed proteins in BCPAP and 8505C cells, sorted in functional categories. Relative intensity of protein spots was calculated normalizing the data to the sum of all spot volumes on gels (Vol%). Each value is the mean of three independent determinations. Vertical bars indicate Vol% values. The protein levels were considered significantly different for ≥ 2 -fold change. The data in the graphs are expressed as mean number \pm SD. For protein symbols, see Table 1.

Table 1 – Catalogue of the differentially expressed proteins in BCPAP and 8505C cell lines. Table reports the following information: Protein names, accession numbers (AC) and abbreviated names correspond to the nomenclature used in the Swiss-Prot database. The experimental values of pI and MW for every isoelectric spot were calculated with ImageMaster 2D Platinum system; the theoretical values represent the predicted MW and pI for each identified protein according to Swiss-Prot and TrEMBL database. Identification methods: 1, MALDI-TOF; 2, N-terminal sequencing by automated Edman degradation; and 3, Western Blotting.

Protein Name	AC Number	Abbreviated Name	Theor. MW	Exp. MW	Theor. pI	Exp. pI	ID methods	% Masses Matched	Sequence coverage (%) N-terminal residues
3-hydroxyisobutyrate dehydrogenase, mitochondrial	P31937	3HIDH	35329	31290	8.38	5,62	1	23	21
Actin, cytoplasmic 1	P60709	ACTB a	41737	42000	5.29	5,02	1,3	36	22
		ACTB fr b		37228		5,37	1	21	34
Anterior gradient protein 2 homolog	O95994	AGR2	19979	16224	9.03	8,83	1	27	50
Aldo-keto reductase family 1 member B10	O60218	AK1BA	36020	36440	7,66	7,11	1	38	36
Aldo-keto reductase family 1 member C3	P42330	AK1C3	36853	37513	8.06	7,68	1	–	30
Retinal dehydrogenase 1	P00352	AL1A1	54862	50636	6.30	6,81	1	61	49
Annexin A1	P04083	ANXA1	38714	36053	6,57	6,48	1	46	52
Annexin A2	P07355	ANXA2 b	38604	36440	7.57	6,88	1	50	15
Annexin A4	P09525	ANXA4 b	35883	33134	5,83	5,71	1	36	64
Calmodulin	P62158	CALM	16838	13928	4.09	4,21	1	57	23
Cyclin-H	P51946	CCNH	37643	36945	6.73	6,61	1	48	38
10 kDa heat shock protein, mitochondrial	P61604	CH10	10932	10902	8.89	8,77	1	40	65
60 kDa heat shock protein, mitochondrial	P10809	CH60 a	61055	59065	5.70	5,00	1,2	28	26, res. 33-38
		CH60 b		59752		5,08	1	78	39
		CH60 c		59500		5,17	2	–	res 33-38
		CH60 sf		54488		5,22	1	38	16
Chloride intracellular channel protein 1	O00299	CLIC1	26923	31861	5.09	4,92	1	48	43
Cofilin-1	P23528	COF1 a	18502	18547	8.22	6,30	1	45	61
		COF1 b		18241		7,08	1	100	52
Coatomer subunit epsilon	O14579	COPE	34482	31384	4,98	5,02	1	17	41
Enoyl-CoA hydratase, mitochondrial	P30084	ECHM	31387	27903	8.34	5,99	1	22	39
		ENOA a	47169	46541	7,01	6,22	3	–	–
		ENOA b		46541		6,37	3	–	–
Alpha-enolase	P06733	ENOA c		46201		6,62	3	–	–
		G3P a	36053	36274	8.57	7,81	1	73	26
		G3P b		36274		8,01	2	–	res. 2-11
Rho GDP-dissociation inhibitor 1	P52565	G3P sf		34355		8,35	1	31	21
		GDIR1	23207	25087	5,01	4,87	1	23	38
75 kDa glucose-regulated protein	P38646	GRP75	73681	74721	5.87	5,34	1	82	24
Hypoxia up-regulated protein 1	Q9Y4L1	HYOU1 fr a	111335	98292	5.16	4,62	1	56	14
		HYOU1 fr b		13586		4,62	1	40	12
Keratin, type I cytoskeletal 9	P35527	K1C9	62064	45528	5.14	5,23	1	18	11
Keratin, type II cytoskeletal 8	P05787	K2C8	53704	39754	5.52	4,86	1	32	24
Pyruvate kinase isozymes M1/M2	P14618	KPYM a	57937	59065	7.96	7,42	1	25	39
		KPYM b		59500		7,64	1	89	53
Galectin-1	P09382	LEG1	14716	12836	5.30	4,95	1	32	61
Lactoylglutathione lyase	Q04760	LGUL	65331	22454	5.12	4,86	1	24	31
Macrophage migration inhibitory factor	P14174	MIF	12476	11539	7.73	7,71	1	80	21
Nuclear transport factor 2	P61970	NTF2	14478	11457	5.10	4,82	1	37	53
Protein disulfide-isomerase A3	P30101	PDIA3 b	56782	54488	5.98	5,85	1	57	27
Phosphoglycerate kinase 1	P00558	PGK 1 b	44615	41872	8.30	7,79	1	43	28
		PGK 1 c		41936		8,06	1	67	13
Peroxiredoxin-1	Q06830	PRDX1 sf	22110	22497	8.27	6,78	1	11	73
Profilin-1	P07737	PROF1 b	15054	13442	8.44	7,57	1	23	56
Proteasome subunit alpha type-1	P25786	PSA1	29556	33335	6.15	6,17	1	100	34
Proteasome subunit beta type 4	P28070	PSB4	29204	23196	5.70	5,50	1	90	34

(continued on next page)

Table 1 (continued)

Protein Name	AC Number	Abbreviated Name	Theor. MW	Exp. MW	Theor. pI	Exp. pI	ID methods	% Masses Matched	Sequence coverage (%) N-terminal residues
Cellular retinoic acid-binding protein 2	P29373	RABP2	15693	13829	5.38	5,41	2	–	res. 1-10
Protein S100-P	P25815	S100P a	10400	51952	4,75	6,36	1	50	33
		S100P b		8625		4,70	1	67	46
Protein S100-A6	P06703	S10A6 a	10180	10786	5.32	4,39	1	100	28
Protein S100-A7	P31151	S10A7 a	11471	9096	6.27	4,99	1	62	39
		S10A7 b		12127		5,52	1	35	35
Protein S100-A13	Q99584	S10AD	11471	10484	5.90	5,96	1	33	44
Adenosylhomocysteinase	P23526	SAHH	47716	43728	5.92	6,07	1	14	30
Superoxide dismutase [Mn], mitochondrial	P04179	SODM	24722	23689	8.35	6,95	2	–	res. 25-34
Serpin B5	P36952	SPB5	42100	39936	5.72	5,76	1	21	27
Tubulin beta-5 chain	P07437	TBB5 a	49671	51008	4.78	4,76	1	52	58
Triosephosphate isomerase	P60174	TPIS b	30791	26669	5.65	6,22	1	77	38
Ubiquitin carboxyl-terminal hydrolase isozyme L1	P09936	UCHL1	24824	26264	5.33	5,34	1	71	67
V-ATPase subunit F	Q16864	VATF	13370	10902	5.29	5,10	1	77	68
Vimentin	P08670	VIME	53652	44865	5,05	4,53	1	51	43
Vinculin	P18206	VINC b	123799	119845	5.50	6,04	1	25	30

3.3.9. Carrier and scaffold proteins

This group includes 3 protein forms, GDIR1, RABP2 and COPE. A higher expression level was detected in 8505C cells for GDIR1, while RABP2 and COPE appeared under-expressed.

A diagram reporting the positive and negative variations of protein expression in logarithm scale and grouped by class is illustrated in Fig. 5.

3.4. Cell motility

Fig. 6 shows the sequential steps of the process of “healing” that both cell lines have undergone. Significant cell migration was seen at 6 h after the scratch only for the 8505C cells, with formation of cell protrusions and intercellular contacts at the wound margins. After 24 h the scratch was completely covered by the 8505C cells, differently from the BCPAP cells which appeared unable to cover the scratch by active migration.

3.5. Gelatinolytic activity

To verify the capability of cells to produce gelatinolytic enzymes, mainly MMP-2 and MMP-9, as potential invasivity markers, the conditioned media collected from BCPAP and 8505C cells respectively, were tested by gelatin zymography, performed after protein separation by mono-dimensional SDS-PAGE. Fig. 7(A) shows the results of a representative zymogram of BCPAP and 8505C conditioned media loaded with the same protein concentration (10 µg/lane). BCPAP sample (lane 2) contained only two faint gelatinolytic bands corresponding to monomeric pro-MMP-9 (92 kDa) and pro-MMP-2 (72 kDa). On the contrary, 8505C sample (lane 3) showed a higher activity of the pro-enzymatic forms (pro-MMP-9 and pro-MMP-2), but also displayed a band corresponding to MMP-9 (86 kDa), co-migrating with immune-stained standards (Fig. 7(B)).

4. Discussion

Thyroid carcinomas are still an open field of studies because of their numerous histotypes and subtypes with unclear biological characteristics. In particular, studies of the thyrocyte and thyroid cancer proteomics, both *ex vivo* [26–29] and of cell lines [25] are in a minority compared with studies of the genome and transcriptome [30,31].

In the present research we aimed at investigating proteomic and phenotypic properties that would increase the possibility to better characterize malignant forms of thyroid tumours. To this purpose, we performed a comparative analysis of two thyroid cancer cell lines, derived respectively from papillary (BCPAP) and anaplastic (8505C) thyroid carcinomas.

Observations at optical and scanning electron microscopes highlighted a large phenotypical diversity between the two cell lines. The BCPAP cells display a rather uniform cellular size, a regular cell shape and plasma membranes decorated by short microvillous expansions. Moreover, in most cases, cells at sub-confluence tend to form circular hollow structures which resemble the follicular structures of the gland. On the contrary, the 8505C cells display very irregular cellular morphology, they grow faster with propensity to overgrow in multilayer, and produce long cell surface protrusions of variable size, typical of very aggressive neoplastic cells [18].

Our proteomic analysis highlighted relevant differential expression of proteins and protein clusters, well matching with the cell behaviours of the two cell lines respectively.

Firstly, it is interesting to notice that the higher expression of proteins stimulating cell proliferation (CCNH, GDIR1 and MIF) [32–34] is detected in the 8505C cells showing higher growth rates than the BCPAP cells. Conversely a lower expression of proteins belonging to the folding control machinery may testify an impaired capability of the 8505C




Fig. 6 – Migration of BCPAP and 8505C cells in a scratch wound assay. Panel shows the representative optical micrographs of B-CPAP and 8505C cells at 0 h, 6 h and 24 h from scratch (magnification: 10×).

cells to perform differentiated cellular functions. An emblematic example is the decrement of the PDIA3, a protein that binds immature forms of thyroglobulin in the exocytosis and endocytosis pathways of thyrocytes, associated with hormonogenesis [35]. These results are in good agreement with the persistence of proliferative activities, in the absence of cell differentiation, as occurs in the anaplastic cancer.

Another significant property of most malignant tumours is the phenomenon of enhanced anaerobic metabolism, described as the “Warburg effect”, which induces acidification of the cancer environment stimulating the development of a more aggressive and invasive phenotype. In our system we observed a higher amount of the glycolytic enzymes in 8505C cell line compared to the BCPAP, in agreement with the malignant properties of these cells. It is also relevant to recall that, in addition to the canonical functions, most glycolytic enzymes perform other cellular functions. For example, in some cases ENOA is expressed at the cell surface, where it may also act as a plasminogen receptor [36], thus mediating the activation of plasmin and consequent extracellular matrix

degradation and cancer invasion. Similarly, the PGK1, another over-expressed glycolytic enzyme in the 8505C cells, may be secreted extracellularly by tumours. In these cases, it represents a critical target of the “chemokine axis” and an important regulator of the “angiogenic switch”, essential for tumour growth and metastasis. In addition, PGK1 is known to regulate the E-cadherin/ β -catenin complex [37], suggesting that over-expression of this protein in tumours may promote decreased cell-cell adhesion and potentiate cell migration.

A differential expression of cytoskeleton proteins was also observed between the two cell lines, probably related with the observed alterations in the 8505C cell shape and polarity. In particular, the high expression level of COF1 in 8505C may have a role in the formation of membrane protrusions and directional spikes which are known to be associated with a motile and invasive phenotype [38]. Moreover, the COF1 plays a crucial role in the apoptotic process, as described in several researches [39,40]. In addition, the decreased expression of the epithelial markers K1C9 and K2C8, associated with the appearance of the mesenchymal marker VIME and with the




Fig. 7 – Detection of gelatinolytic activity. The figure displays: A) Representative gelatin zymogram 7.5% SDS-PAGE of conditioned medium samples from BCPAP (lane 2) and 8505C (lane 3) cells and serum sample (lane 1) used as molecular weight marker; and B) Western Blotting of purified gelatinases revealed with anti-MMP-2 (lane 1) and anti-MMP-9 (lane 2) monoclonal antibodies.

up-regulation of ANXA1, a protein involved in the membrane trafficking and TGF- β signaling [41], may testify the occurrence of the epithelial–mesenchymal transition and the consequent acquisition of a more invasive and aggressive phenotype. Indeed, other proteins in the 8505C cell proteomics are described as associated with the tumour growth and metastatic progression: i.e. the S100A6 [42] and LEG1, which, among several functions, is also considered a co-promoter of MMP-2 and MMP-9 expression [43] and therefore an enhancer of tumour invasion and metastasis. In support of this hypothesis is the observation that the 8505C cells produce and release into the medium a significant quantity of matrix metalloproteinases MMP-2 and MMP-9.

5. Conclusions

The phenotypical features and *in vitro* behaviours of the BCPAP and 8505C cell lines, object of the present study, are indicative of the different malignant potentiality of the tumours from which the cells were derived. Indeed, the BCPAP cells display traits of well differentiated non-invasive cells, while the 8505C cells clearly show the expected characteristics of a very aggressive phenotype *in vivo*. The major features are: the exhibition of a high growth rate, the loss of the epithelial cell polarity, the transition from epithelial to mesenchymal cytoskeletal markers, the attitude to cell migration, as demonstrated by the scratch assay, the extension of long surface protrusion and cell membrane ruffling, the ability to produce matrix degrading enzymes (MMPs). Remarkably, the proteomic profiles are in agreement with phenotypical traits which characterize the two

studied cell lines. These include: the over-expression of the glycolytic enzymes by the 8505C cells, which recall the *in vivo* Warburg effect typical of malignant tumours; the differential expression of cytoskeleton proteins, responsible for cell shapes and cell motility; the differential expression of many proteins responsible for cell proliferation, and others belonging to other functional classes. Finally, it is worth mentioning that the majority of the identified proteins are able to perform a variety of cellular functions, besides their canonical primary roles, that when deregulated may become instrumental for cancer growth and invasion. The differentially expressed proteins may be used for future applications as biomarkers of thyroid malignancy.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.jprot.2013.01.023>.

Acknowledgements

The present work was supported in part by PhD funds to R.M. by the University of Palermo, and in part by 5 \times 1000 State-made contributions to C.O.B.S. for distinguished no-profit research associations.

REFERENCES

- [1] Pellegriti G, De Vathaire F, Scollo C, Attard M, Giordano C, Arena S, et al. Papillary thyroid cancer incidence in the volcanic area of Sicily. *J Natl Cancer Inst* 2009;101:1575–83.
- [2] Ain KB. Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches. *Thyroid* 1998;8:715–26.
- [3] Takano T, Amino N. Fetal cell carcinogenesis: A new hypothesis for better understanding of thyroid carcinoma. *Thyroid* 2005;15:432–9.
- [4] Lin RY. New insights into thyroid stem cells. *Thyroid* 2007;17:1019–23.
- [5] Mitsutake N, Iwao A, Nagai K, Namba H, Ohtsuru A, Saenko V, et al. Characterization of side population in thyroid cancer cell lines: Cancer stem-like cells are enriched partly but not exclusively. *Endocrinology* 2007;148:1797–803.
- [6] Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, Coppola A, et al. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. *PLoS One* 2008;3:e3544.
- [7] Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: Implications for tumour origin, diagnosis and treatment. *Mod Pathol* 2004;17:1359–63.
- [8] Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumours are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. *J Clin Endocrinol Metab* 2003;88:5399–404.
- [9] Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. *Endocr Pathol* 2004;15:319–27.
- [10] Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. *Cancer* 2005;103:2261–8.
- [11] Pucci-Minafra I, Cancemi P, Marabeti MR, Albanese NN, Di Cara G, Taormina P, et al. Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts. *Proteomics Clin Appl* 2007;11:118–29.

- [12] Pucci-Minafra I, Cancemi P, Albanese NN, Di Cara G, Marabeti MR, Marrazzo A, et al. New protein clustering of breast cancer tissue proteomics using actin content as a cellularity indicator. *J Proteome Res* 2008;7:1412–8.
- [13] Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, et al. Large-scale proteomic identification of S100 proteins in breast cancer tissues. *BMC Cancer* 2010;10:476.
- [14] Paulin C, Fabien N, Fusco A, Pages MP, Patricot MC, Bornet H, et al. Description of a cell line arising from a human thyroid papillary carcinoma and synthesizing the human chorionic gonadotropin hormone. *C R Acad Sci III* 1992;315:493–8.
- [15] Ito T, Seyama T, Hayashi Y, Hayashi T, Dohi K, Mizuno T, et al. Establishment of 2 human thyroid-carcinoma cell-lines (8305c, 8505c) bearing p53 gene-mutations. *Int J Oncol* 1994;4:583–6.
- [16] Cancemi P, Albanese NN, DiCara G, Marabeti MR, Costantini F, Minafra S, et al. Multiple changes induced by fibroblasts on breast cancer cells. *Connect Tissue Res* 2010;51:88–104.
- [17] Pucci-Minafra I, Minafra S, La Rocca G, Barranca M, Fontana S, Alaimo G, et al. Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A [MMP-2] and B [MMP-9] separated by mono- and two-dimensional electrophoresis. *Matrix Biol* 2001;20:419–27.
- [18] Pucci-Minafra I, Cancemi P, Di Cara G, Minafra L, Feo S, Forlino A, et al. Decorin transfection induces proteomic and phenotypic modulation in breast cancer cells 8701-BC. *Connect Tissue Res* 2008;49:30–41.
- [19] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248–54.
- [20] Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, et al. Differential occurrence of S100A7 in breast cancer tissues: A proteomic-based investigation. *Proteomics Clin Appl* 2012;6:364–73.
- [21] Pucci-Minafra I, Fontana S, Cancemi P, Alaimo G, Minafra S. Proteomic patterns of cultured breast cancer cells and epithelial mammary cells. *Ann NY Acad Sci* 2002;963:122–39.
- [22] Pucci-Minafra I, Fontana S, Cancemi P, Basiricò L, Caricato S, Minafra S. A contribution to breast cancer cell proteomics: Detection of new sequences. *Proteomics* 2002;2:919–27.
- [23] Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C. Description of a human papillary thyroid carcinoma cell line. *Cancer* 1994;73:2206–12.
- [24] <http://david.abcc.ncifcrf.gov/>.
- [25] Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, et al. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. *J Endocrinol Invest* 2005;28:137–44.
- [26] Ban Y, Yamamoto G, Takada M, Hayashi S, Ban Y, Shimizu K, et al. Proteomic profiling of thyroid papillary carcinoma. *J Thyroid Res* 2012;2012:815079.
- [27] Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, et al. Proteomic profiling of follicular and papillary thyroid tumors. *Eur J Endocrinol* 2012;166:657–67.
- [28] Giusti L, Iacconi P, Ciregia F, Giannaccini G, Donatini GL, Basolo F, et al. Fine-needle aspiration of thyroid nodules: Proteomic analysis to identify cancer biomarkers. *J Proteome Res* 2008;7:4079–88.
- [29] Braunschweig T, Kaserer K, Chung JY, Bilke S, Krizman D, Knezevic V, et al. Proteomic expression profiling of thyroid neoplasms. *Proteomics Clin Appl* 2007;1:264–71.
- [30] Haugen BR, Duncan MW. Applications of proteomics to thyroid neoplasms: Are we there yet? *Thyroid* 2010;20:1051–2.
- [31] Saiselet M, Floor S, Tarabichi M, Dom G, Hébrant A, van Staveren WC, et al. Thyroid cancer cell lines: an overview. *Front Endocrinol (Lausanne)* 2012;3:133.
- [32] Kayaselcuk F, Erkanli S, Bolat F, Seydaoglu G, Kuscu E, Demirhan B. Expression of cyclin H in normal and cancerous endometrium, its correlation with other cyclins, and association with clinicopathologic parameters. *Int J Gynecol Cancer* 2006;16:402–8.
- [33] Zhao L, Wang H, Li J, Liu Y, Ding Y. Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer. *J Proteome Res* 2008;7:3994–4003.
- [34] Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. *BMC Cancer* 2004;4:34.
- [35] Mezghrani A, Courageot J, Mani JC, Pugniere M, Bastiani P, Miquelis R. Protein-disulfide isomerase [PDI] in FRTL5 cells. pH-dependent thyroglobulin/PDI interactions determine a novel PDI function in the post-endoplasmic reticulum of thyrocytes. *J Biol Chem* 2000;275:1920–9.
- [36] Redlitz A, Fowler BJ, Plow EF, Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. *Eur J Biochem* 1995;227:407–15.
- [37] Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, et al. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. *Cancer Res* 2007;67:149–59.
- [38] Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. *Nat Rev Cancer* 2007;7:429–740.
- [39] Chua BT, Volbracht C, Tan KO, Li R, Yu VC, Li P. Mitochondrial translocation of cofilin is an early step in apoptosis induction. *Nat Cell Biol* 2003;5:1083–9.
- [40] Bernstein BW, Bamberg JR. ADF/cofilin: A functional node in cell biology. *Trends Cell Biol* 2010;20:187–95.
- [41] de Graauwa M, van Miltenburga MH, Schmidt MK, Ponta C, Lalaia R, Kartopawiroa J, et al. Annexin A1 regulates TGF- β signaling and promotes metastasis formation of basal-like breast cancer cells. *PNAS* 2010;6:6340–5.
- [42] Leśniak W, Słomnicki ŁP, Filipek A. S100A6—new facts and features. *Biochem Biophys Res Commun* 2009;390:1087–92.
- [43] Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, et al. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. *Mol Cancer Res* 2009;7:311–8.